Stay updated on LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:15:28.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study details related to the safety evaluation of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab for participants with advanced solid tumors in a Phase 1a/1b trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:57.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. The new description emphasizes the importance of these criteria in selecting participants for clinical research.
    Difference
    27%
    Check dated 2024-05-22T21:25:47.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:29:05.000Z thumbnail image

Stay in the know with updates to LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the LY3022855 Combo with Immunotherapy in Solid Tumors Clinical Trial page.